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Abstract

Introduction

Over the past decade, the field of molecular biology
has given rise to the development of the applied discipline of molecular medicine. Based on recent developments using recombinant gene technology, genetic mapping analysis and other investigational tools, the physician and surgeon is now ready to begin using those
instruments in the diagnosis and treatment of musculoskeletal disease. This article reviews the history of
scientific exploration in recombinant gene technology as
it applies to bone and cartilage repair. Clinical cases are
presented to show how the fruits of scientific knowledge
may be brought to bear on some of the more challenging
musculoskeletal problems. Although some of these examples may prove to be accurate representations of how
molecular engineering will be used in specific clinical
settings, the purpose of this review is to provide an
orientation and philosophical approach to the applications
of recombinant gene technology in traumatic and reconstructive surgery of the skeleton.

The growth of scientific information appears to
develop in a logarithmic -like fashion as opposed to a
linear one. Each new piece of data acquired and each
new technique developed leads to advances in scientific
knowledge which accelerate technology by orders of
magnitude. This growth of knowledge in the areas of
bone and cartilage repair will soon be realized in our
clinics and operating rooms. This article will briefly
review the history of scientific developments which have
lead up to the present state of technology in this field,
and provide a vision of how this technology may be
applied clinically.
To begin to understand how new scientific advances
might be used in patients, it is important to identify the
incidences and associated costs of the most commonly
occurring conditions which require medical and surgical
intervention. According to recent studies, it is estimated
that approximately 200,000 bone graft operations 3 and
265,000 total joint procedures4 are performed in the
United States each year. In addition, 5.6 million
traumatic fractures result in a 5-10 % non-union rate3
and about 1.5 million pathologic fractures are sustained
in osteoporotic patients annually 16 . The cost to the
American economy of osteoporosis alone is in excess of
ten billion dollars 16 .
Since cost has become a major factor in the allocation of medical services, scientists, universities, and
biotechnology companies are now finding that cost plays
an important role in directing research and development.
It is important to recognize, however, that cost is measured in many ways. Work loss, early retirement, and
monetary loss are among some of the costs incurred by
a medical condition. It is therefore necessary to consider all costs when allocating expenditures to the study
and treatment of specific diseases. It can be anticipated
that the results of ongoing federally-driven outcome
studies will determine which technologies are most costeffective17. These findings will almost certainly lead to
decisions on how research dollars are allocated in the
future 17 .
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Table 1: Milestones in Induced Osteogenesis
1889

Senn21

First therapeutic use of decalcified bone (in canines)

1917

Neuhof14

Induced osteogenesis by urinary epithelium

1965

Urist25

Induced osteogenesis by demineralized bone matrix (DBM)

1968

Urist26

First successful use of decalcified bone in patients

1972

Reddi and Huggins 15

1981

Sampath and

Reddi 20

1988

Wozney et al. 30

Induced osteogenesis as model of cellular differentiation
Extraction and reconstitution of the bone inductive property from DBM
Recombinant production of BMPs

protein" (BMP) 28 . By the end of the 1980' s, orthopaedic trauma surgeons at UCLA Medical Center, under
Urist's direction, implanted partially purified human
BMP into phalangeal cavities29 , non-union defects in the
tibia9 and femur 8 and eventually fresh traumatic defects
in the tibia 10 . Some of these operations were combined
with local and free-flap soft tissue procedures to
optimize the biological environment of the host bed.
The early results demonstrated healing capacities similar
to (and in some cases, better than) autogenous bone graft
procedures. In most instances, the need to make an
additional incision in order to harvest autogenous bone
was obviated and, as a result, operative morbidity was
reduced significantly.
Because it has been recognized that the yield of
BMP from cadaveric allogeneic bank bone is limited,
and because it has been learned that this inductive
protein may work in a more optimal fashion when it is
implanted along with other specific substances contained
in DBM (e.g., transforming growth factor-beta) efforts
have been initiated to develop recombinant technologies
for the production of sufficient quantities of certain
cytokines and growth factors. The scientific contribution
of Wozney and co-workers 30 was an important step in
that direction. Using highly technical cloning and DNA
sequencing techniques, these investigators began to
express these factors in large quantities for potential
clinical use. Presently, experiments are being conducted
to investigate the biological activities of specific factors
and how they may work when used in combination with
each other.
Research in the field of growth factor and cytokine
function is one of the most active areas of scientific
exploration to date. Although it would be ideal to be
able to provide a list of the current known factors and
bow they are expected to function biologically, this information is not sufficiently clear at this time. Nevertheless, based on what is known presently, it can be
anticipated that certain key factors will achieve a

Historical Perspectives
The progress of research on bone and cartilage repair has been punctuated by the important contributions
of several key investigators (Table 1). One of the first
pioneers in this area was Senn, a late 19th century surgeon. Using decalcified bone from the ox tibia as a
delivery system for an antiseptic (iodoform), Senn attempted to treat osteomyelitis in the skulls of dogs21 .
Although his main purpose was to eradicate the infections, he reported that this treatment led to the osseous
healing of the bone cavities21 . Later, in 1917, Neuhof
described the formation of bone in a visceral site in the
urinary tract site under the influence of implanted fascia 14 . Subsequent studies by Huggins5 confirmed these
findings.
In 1965, Marshall R. Urist demonstrated the induction of ectopic new bone in laboratory animals by the
implantation of demineralized bone matrix25 . Urist
followed this report in 1968 by describing the first
successful clinical use of demineralized bone in the
treatment of ten patients2 6 . These findings stimulated
the interest of other scientists such as Reddi and
Huggins 15 who showed that the phenomenon of induced
osteogenesis was essentially a model of cellular differentiation. By the early 1980's, clinical investigators had
begun using dernineralized human allogeneic bone in the
treatment of several osseous defects. The use of this demineralized bone matrix was applied to the reconstruction of maxillocraniofacial deformities2• 11 • 13 , phalangeal cavities in the hand24 • 29 and in the augmentation of
spinal fusions 27 . Today, this bone graft substitute
material (DBM) is commercially available from several
companies.
Using highly efficient cfrotein purification technologies Sampath and Reddi 2 were the first to extract a
specific bone inductive property from demineralized
bone matrix. U rist succeeded in extracting a similar
factor and he named this substance "bone morphogenetic
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Table 2: Clinical Applications of Biological Factors

therapeutic role in clinical medicine. BMP, for example, is one of a group of related peptides which are part
of the TGF-,6 superfamily. Peptides in this family may
have far reaching effects ranging from the regulation of
cell replication and differentiation to the control of bone
resorption. As noted above, BMP has already been
shown to have a role in inducing osteogenesis in
patients. Other factors such as the interleukins and
hematopoietic growth factors have been shown to regulate specific cellular activities in certain types of diseases. By extrapolating these findings to other clinical
settings , it is possible to envision a broad role for these
factors in the treatment of musculoskeletal disease.

Condition

Clinical Applications
Based on the early clinical results of induced
osteogenesis , clinicians can now envision a variety of
applications of bone morphogenetic proteins and other
biological factors. To imagine how these factors may be
applied, it is necessary to identify the clinical conditions
which would benefit most from their use. In addition ,
these applications must be considered in relation to the
alternatives which are presently available. Table 2
shows a partial list of those conditions for which the
application of biological factors may become important.
Since an approach to improving upon the treatments of
these conditions must be guided by specific goals, it is
necessary to identify what it is that the clinician requires
in order to achieve these objectives.
The factors whose applications are previewed in this
article are specific polypeptide products of cells that can
function as bone and/or cartilage growth factors, hematopoietic colony stimulating factors, attachment-promoting proteins, or other biologic response modifiers which
induce speci fie target cells or affect the response of
these cells to other stimuli. However, in any given clinical setting, the responses which the clinician would require these factors to modulate are not necessarily of
equal importance. Therefore, it is necessary to prioritize these responses by first identifying clinical "needs"
and following this by the identification of specific
clinical "wants".
In terms of "needs", the clinician and/or scientist
must begin with the premise that a wound will not heal
and a bone will not grow unless there exists an optimal
systemic environment, an optimal systemic response, an
optimal local environment, and an optimal local response. It would therefore be desirable to have both
locally and systemically injectable6, or implantable23 ,
materials which could ensure that these conditions will
be present (e.g., such as normalizing the systemic and
local response in a diabetic patient who has a soft tissue
wound of the foot). If technology could accomplish this

Present Alternatives

Fracture Healing

Auto graft/ Allograft
Ceramics
Distraction Osteogenesis

Cartilage Repair

None
(Continuous Passive Motion?)

Osteoporosis

Antiresorptive Drugs

Implant Stabilization

Auto graft/ Allograft
Ceramics

Osteonecrosis

Core Decompression
Vascularized Autograft
Electrical Stimulation

Tumor Reconstruction Allograft
Metal Implant
Distraction Osteogenesis
Vascularized Autograft
Joint Reconstruction

Allograft
Metal Implant

Osteopetrosis

Bone Marrow Transplantation

Wound Healing in
Debilitated Patients

Debridement/Skin Grafts

goal and provide for these "needs", it might become apparent that the human organism already has the necessary biological mechanisms for healing many conditions.
Beyond the question of "needs" of course, is the
question of "wants". Here the clinician is dealing with
a situation whereby the biologic response desired is
beyond the capacity of the human system even under the
most optimal set of conditions (e.g., such as regenerating a dead femoral head or replacing a large hyaline cartilage defect in a joint). Factors which the clinician
would "want" to have in order to accomplish these goals
could include chemotactic, attachment, competence, progression, and inductive factors, as well as conductive
surfaces, delivery systems and possibly pluripotent stem
cells.
Chemotactic factors could be extremely valuable for
the purpose of attracting the migration or ingrowth of
progenitor cells to the area of a wound. Factors which
may possess this activity include TGF-,6 and platelet derived growth factor (PDGF). Attachment factors could
function not only to maintain these newly attracted cells
in this wound repair environment but also to influence
their proliferative capacity and optimize their phenotypic
expression. Examples include fibronectin, osteopontin
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original fracture in the above case (and this could be
done with a percutaneous needle and radiographic realtime visualization), perhaps the fracture would have
healed within the expected time frame of three to four
months. The patient would have been back to her normal activities within four or five month's time.
Currently, the Food and Drug Administration appears to be focusing on patients with existing non-unions
as prime subjects for inclusion in studies to test the
effects of osteogenic substances. While it is understandable why these patients are appropriate subjects for
clinical trials of this nature (they already have a problem
as opposed to being at risk for potentially developing
one), it must be recognized that the response of a nonunion to an implanted osteogenic substance may be entirely different from that of a fresh fracture. In the
former, the host bed consists of an admixture of fibrous
tissue and cartilage while in the latter, the host bed
consists of a fresh hematoma in the midst of an acute inflammatory response. These differences could play significant and important roles in determining the types of
cells present and the nature of their responses to injectable or implantable substances. Based on a knowledge of
which types of fractures are at greatest risk for developing problems with healing, it should be possible to
identify those fractures at the time of injury and
intervene in a prophylactic manner using the appropriate
inductive therapy.

and thrombospondin. Competence factors function to
prepare a cell to undergo a change in its cell cycle and
thus may favorably alter its response to exogenous signals. Insulin and PDGF may possibly function in this
manner. Progression factors stimulate cell division and
proliferation and result in the production of sufficient
numbers of cells of a specific type to ultimately produce
new tissue. A variety of factors may be capable of this
activity. These would include TGF-,B, PDGF, insulinlike growth factors (IGF-I and IGF-II), fibroblastic
growth factors (aFGF and ,BFGF) and Interleukin-1. Inductive factors stimulate differentiation and differentiated
function and could be of major importance in mediating
wound healing and matrix production. Most members
of the TFG-,B superfamily, including BMP, are presumed to possess this ability.
To use these factors in patients, it will be necessary
to have a delivery system which will bring the factors
into contact with the target cells, protect them from immediate degradation in the host, and control the kinetics
of their release such that their timing of appearance,
local concentration, and inhibitory and stimulatory functions are properly coordinated. Finally, all of these factors could potentially lead to more rapid and predictable
healing if, specifically responsive, immunologically controlled, pluripotent stem cells were available for local
implantation.
With these considerations in mind, the following
clinical cases are presented to show how molecular
engineering may be applied to musculoskeletal disease:

Case Nwnber 2 - Articular Cartilage Defect
A twenty-four year old healthy white female fell
down a flight of steps and sustained a direct blunt contusion to her right knee. Eighteen months later, she continued to experience significant medial joint pain. An
arthroscopic examination showed a 2.5 cm diameter area
of cartilage degeneration (chondromalacia) without any
evidence of healing. Treatment consisted of arthroscopic debridement and drilling of the subchondral bone in
a weak attempt to stimulate a reparative response which
could potentially lead to fibrocartilage production. Postoperative management consisted of a continuous passive
motion protocol and intensive physical therapy. Currently, the patient is mildly improved but still experiences pain in the area of the original injury.

Case Nwnber 1 - Tibial Non-Union
A forty-one year old healthy white female slipped
on an icy sidewalk and sustained a comminuted fracture
of her right distal tibia and fibula (Figure 1). Standard
conservative orthopaedic management in a cast led to delayed union after nine months. Pulsed electromagnetic
stimulation for an additional three months failed to result
in healing. The fracture was ultimately treated with
open reduction and internal fixation. Healing occurred
four months later. However, as a result of the long
period (approximately 16 month) during which time she
was unable to put weight on her leg, significant disuse
osteoporosis developed throughout the tibia (Figure 2).
The patient required an additional twelve months of intensive physical therapy in order to regain normal motion, bone mass and ambulatory function. As a result of
her being out of work during most of this period of
time, the patient lost her job and has not returned to the
work force.

Comment
Most studies have shown that hyaline cartilage has
very limited potential for tissue repair and almost no
ability to heal large defects 18 . When articular cartilage
injuries extend through the entire thickness of the cartilage and into subchondral bone, any healing response
which is seen is usually initiated by the subchondral osseous tissue. Some reports suggest that motion of an injured joint in a continuous passive manner results in the
formation of fibrocartilage which can provide articular

Comment
Prevention of non-union is perhaps the most obvious
indication for the use of an osteogenic substance. If
such a substance were to have been injected into the
4

Recombinant Gene Technology in Bone and Cartilage Repair
stimulate chondrogenesis, it should be possible to introduce it into the injury site in a joint with minimal surgical trauma. In a case such as the one presented above,
one could envision a scenario whereby the patient undergoes an arthroscopic procedure in which the host bed is
prepared by surgical debridement, followed by the coating of the exposed bone surface with a chondrogenic
substance. Alternatively, an attachment-promoting material could be implanted (e.g., RGD-containing), and this
could serve to anchor cultured chondrocytes embedded
in a chondrogenic delivery system. Both of these techniques could be followed by rehabilitation protocols using continuous passive motion and other physical modalities to enhance the healing and functional recovery.

Case Number 3 - Total Hip Arthroplasty
A thirty year old black male developed spontaneous
osteonecrosis of the hip. He presents with hip pain of
one year's duration and an X-ray showing Stage IV
osteonecrosis of the left femoral head (Figure 3). All
attempts at conservative management have failed and no
surgical procedure which would leave his own femoral
head intact would appear to be effective. A total hip
replacement was performed with a non-cemented,
porous-coated prosthesis. The post operative X-ray
(Figure 4) shows distal intimate contact between the
stem and the endosteal surface of the femoral cortex.
Proximally, the degree of bone-implant contact is less
optimal.

Comment
This case describes an all-too-commonly occurring
situation in which the only reasonable therapeutic option
for a young patient with a diseased hip joint is an artificial joint replacement. While total hip replacement arthroplasty has been an extremely successful operation in
the treatment of elderly patients with osteoarthrosis, its
use in young patients has been much less successful.
This has been attributed mainly to the fact that the long
lasting durability of cemented implants is usually limited
to not more than ten to fifteen years. While the new age
of porous-coated hip implant technology has offered the
hope that these implants will perform in a superior manner over time, the long term results are not yet available. It is presently thought that two factors which may
influence these results will be, 1) the ability of bone to
grow into the surface of the prosthesis, and 2) the way
this ingrowth affects the stress environment and remodeling response of the skeleton. Biologically, one can
only expect bone to grow into a prosthesis when the
contact between the two is sufficiently intimate.
As examples of how a lack of bone ingrowth could
potentially lead to problems, consider the radiographs of
the two cases shown in Figures 4 and 5. As indicated
above, Figure 4 shows grossly evident contact between

Figure 1 (at left). Anterior-posterior radiograph of the
right lower leg taken immediately after ankle injury in
a forty-one year old female. Note the presence of a
mildly displaced, severely com.minuted fracture of the
distal tibia and fibula.

Figure 2 (at right). Anterior-posterior radio graph of
the same lower leg shown in Figure 1 taken 16 months
after the initial injury. Note the presence of plates and
screws which were used to fix this fracture 12 months
after injury. Although fracture healing is evident, there
is now significant disuse osteoporosis.
cartilage function 19 . How well tissue forms in large
defects and how well it functions in the long-term remains an unanswered question.
With the advent of advanced arthroscopic surgical
techniques and the development of new instrumentation,
orthopaedic surgeons are now capable of doing many
operations in joints using relatively atraumatic approaches. If a substance were available which could
5
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Figure 3 (facing page at top). Anterior-posterior radiograph of the pelvis of a thirty-year old black male. Note the
presence of Stage IV osteonecrosis of the left femoral head.
Figure 4 (facing page, bottom left). Anterior-posterior radiograph of the hip taken immediately after implantation of
a non-cemented, porous-coated total hip system in the patient whose X-rays are shown in Figure 3. Note excellent distal
bone-implant contact of the femoral component. Proximally, femoral bone implant contact is questionable.

Figure 5 (facing page, bottom right). Anterior-posterior radiograph of the same type of non-cemented, porous-coated
total hip system shown in Figure 4. Note that in this patient, there is a complete line of radiolucency surrounding the
entire femoral component suggesting poor contact between the implant and the bone.
the distal part of the stem and the intramedullary canal
of the femur. However, proximally, contact is questionable. The long term results of bone remodeling could
potentially lead to bone hypertrophy distally with disuse
osteoporosis proximally. This could result in a biomechanical cantilever system whereby proximal motion
and distal fixation leads to fatigue fracture of the metal
implant. In Figure 5, another young patient underwent
a similar operation in which very little contact between
the prosthesis and the bone existed anywhere. This
implant remained unstable and required revision surgery
within one year of the original operation.
The ability to obtain intimate contact between a
prosthesis and the bone, and to do it in the appropriate
places, is beyond the capability of even the most skilled
surgeon. The development of a material which could be
applied to a prosthesis to promote bone ingrowth, even
without close and intimate contact, would make the technology of non-cemented joint replacement surgery potentially much safer and reliable. Since bone remodels
around such implants in response to mechanical forces,
the ability of the surgeon to determine where bone ingrowth should occur and where it should not, may enhance his or her ability to control the stress environment
and optimize the results. Presently available materials
such as hydroxyapatite coatings and different types of
surfaces are only passively conductive and may ultimately prove to be inadequate for achieving these goals.

portion of the femoral head remain alive. In this case,
it is assumed that the entire femoral head was necrotic
and thus not salvageable in its present form. Some have
advocated using vascularized fibular auto graft transplants
or bone-muscle pedicle flaps from the lesser or greater
trochanters but the successes of these procedures alone
are unreliable. A more predictable and successful surgical outcome could potentially result if these vascularized
transplants could be combined with growth factors and
perhaps pluripotent stem cells. One could envision a
procedure in which the necrotic femoral head is excavated such that it is hollow with the exception of a thin
shell of subchondral bone and articular cartilage. Into
this shell could be implanted a vascularized fibular autograft or bone muscle-pedicle flap. This graft could then
be surrounded by a composite implant of inductive and
cell attachment proteins incorporated in a deli very system to enhance osteogenesis.

Biologic Response Modifiers: Early Clinical Results
A variety of immunomodulatory proteins and hematopoietic colony stimulating factors have been used in
the treatment of immunosuppressed patients. Several of
these factors have undergone testing in phase I and
phase II clinical trials and others have even achieved
FDA approval for specific indications. Colony stimulating factors such as granulocyte-colony stimulating factor
and granulocyte macrophage-colony stimulating factor
have achieved FDA approval for the treatment of
patients with failed bone marrow grafts and chemotherapy-induced leukopenia.
The preliminary clinical results from studies using
these biologic response modifiers will pave the way for
their potential applications in the treatment of musculoskeletal disease. Not only has it been shown that many
of these factors are involved in bone and cartilage formation, turnover, and degradation, but specific metabolic
bone diseases may be related to deficiencies of one or
more of these factors. Recent evidence that a defect in
the structural gene responsible for the production of
macrophage-colony stimulating factor (M-CSF) is present in animals with a specific form of osteopetrosis31 ,
combined with evidence that treatment of these animals

Case Nwnber 4 - Trawnatic Osteonecrosis of the Hip
A thirty year old healthy white male suffered a traumatic dislocation of his right hip while playing softball.
An attempted closed reduction in a local emergency
room converted this injury to a fracture dislocation
(Figure 6). Open reduction and internal fixation was
performed however, three months later, there was no
evidence of healing and a bone scan showed photopenia
of the right hip consistent with ischemic necrosis (Figure
7). As a result, this young patient underwent hip
arthroplasty with a bipolar prosthesis.

Comment
While the treatment of traumatic ischemic necrosis
of the femoral head is still controversial, most femoral
head-sparing procedures require that some significant
7
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Figure 6. Anterior-posterior radiograph of
the right hip in a thirty year old male who
had just undergone attempted closed reduction for a hip dislocation. This X-ray now
shows the presence of a complete fracturedislocation of the femoral head and neck.
Figure 7. Technetium-99m methylene diphosphonate (MDP) bone scan of the pelvis
of the patient shown in Figure 6. Note the
increased isotopic activity in the acetabulum
and trochanteric areas of the right hip with
complete photopenia of the right femoral
head.
This study was interpreted as
showing complete necrosis of the right
femoral head.
Figure 8. Lateral radiograph of the hip in
a patient with fibro-dysplasia ossificans
progressiva. Note the presence of an ossified iliopsoas muscle originating in the
pelvis, crossing the groin, and inserting on
the lesser trochanter of the hip.
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with M-CSF cures this condition1, is an example of how
a metabolic bone condition may respond to a hematopoietic colony stimulating factor. Further evidence that
targeted disruption of the c-src proto-oncogene by homologous recombination leads to osteopetrosis in mice22
may provide evidence to support the exploration of new
genetic pathways of investigation of metabolic bone
disorders.

effects have been observed in patients who have been
treated with recombinant biologic response modifiers,
the application of recombinant osteogenic or chondrogenic factors in patients has not been tested extensively.
Teleologically, it is recognized that bone regeneration in humans is possible. This is exemplified by the
phenomenon of normal fracture healing by endochondral
ossification. In this process, new mature bone actually
regenerates in response to an injury. An extension of
this phenomena which has been exploited in patients is
the bone which is regenerated during distraction osteogenesis using the methods originaliy developed by
Ilizarov 7 . In these cases, significant gaps and segments
of the skeleton have been restored by surgical and
mechanical manipulations.
One of the most impressive, and for the purposes of
this di scussion, interesting pathological conditions to
affect the musculoskeletal system is fibrodysplasia
(myositis) ossificans progressiva (FOP) . This is a rare
autosomal dominant disorder characterized by symmetrical congenital malformations of the blastemal anlage of
the hands and feet and by the progressive heterotopic
chondrogenesis and ossification of soft connective tissues 12. It is unknown what triggers this mechanism (although it has been suggested to be related to an injury
and repair process) and no treatment is known. It is an
extremely disabling disorder particularly because the ossified soft tissues generally take the form of fascia!
planes associated with specific muscle groups. In many
cases, this leads to the partial or complete immobilization of the involved joints. Figure 8 shows an ossified
iliopsoas muscle crossing the groin of a twenty-four year
old woman with FOP. This patient is completely unable
to flex or extend her hip joint.
A recent review provided strong evidence to suggest
that FOP is a genetic disorder characterized by a disturbed developmental expression of the endochondral
program and represents a mutation resulting in a dominant gain of function 12 . It was shown that an array of
developmental gradients (characteristic patterns of disease expression) similar to developmental anomalies induced by pleiotropic mutations of the decapentaplegic
(dpp) locus in Drosophila melanogaster may be related
to a 75 % sequence homology between the protein encoded by the dpp locus in Drosophila and the C-terminal
region of two recently cloned human bone morphogenetic proteins (BMP-2A, BMP-2B), members of the TGF/3
superfamily. It was therefore suggested that the genetic
predisposition to develop this phenotype in humans may
be related to bone morphogenetic protein expression 12 .
This case provides evidence that it may be possible to
obtain, in humans, a significant and even massive osteogenic response to a bone morphogenetic protein-like factor. It also suggests that an array of responses in

Questions and Concerns
An important part of the development of any new
medical technology is the careful and systematic evaluation of potential toxic effects. While some of these
effects may be manifest as acute short-term problems, a
much greater concern exists over the possibility of patients developing serious complications which may become obvious only after months or years of treatment.
With regard to the clinical experiences using some of the
biologic response modifiers, examples of these effects
include fever , hypotension, hepatic and renal failure,
myocardial infarction , capillary leak syndrome, and
massive edema, to name a few.
Specificity is another important consideration in the
development of a new therapeutic agent. The greater
the specificity of a factor for its target cell , the greater
control the clinician has over the patient's response.
Furthermore, a biologic response, such as a wound
healing process, may require the participation of several
types of cells at different points in time. Therefore, the
specificity of a factor may change at different times during the response period. The need to develop delivery
systems which not only protect factors from degradation
but also optimize their concentrations and kinetics of release may be critical to the success of any molecular
product. Finding the optimal combinations of factors
may also be critical to the success of this technology.
Although not yet observed, an ever present concern
with regard to growth factors is their potential cancer
producing effects. It would seem intuitive that any factor which has the ability to change a cell's behavior
could possibly lose control over that cell and lead to the
induction of a neoplastic process. One of the most important concerns with regard to the use of molecular engineering in treating diseases and developing new drugs
will be the ability to interrupt an induced process once
it has been initiated.

Expectations for the Future
How well the human organism will respond to cells,
growth factors and other biological materials remains to
be examined. While the responses in lower mammals
have been encouraging, and while significant clinical
9
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humans may be possible by the proper molecular engineering of other factors in the TGFJ] superfamily.
Much has been learned over the past ten years concerning the technologies discussed in this review. The
need to develop these advances into safe and effective
medical treatments is the challenge to today's investigator. The ability to provide these technologies to all patients rich and poor will require the cooperation of scientists, physicians, economists and government officials.
As we enter the age of molecular medicine, the future
looks bright for the treatment of musculoskeletal injury
and disease.
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there are 5.6 million fractures sustained in the United
States each year of which 5 to 10 % result in non-union.
The most common bones affected are the tibia, humerus,
femoral neck and carpal schapoid however, case reports
have shown that nearly every bone in the body is capable of developing a non-union under certain conditions.
The features which generally predispose to non-union
are infection, excessive comminution and bone loss,
extensive soft tissue injury, poor blood supply, poor
systemic nutrition, inappropriate surgical management,
and failure of the patient to comply with the surgeon's
instructions. The use of a bone-promoting substance at
the time of initial fracture treatment may be effective in
preventing a large number of these cases.

M.E. Bolander: It may be important to point out that
there are several bone morphogenetic proteins, and that
these proteins are related to a family of growth factors
called the TGF-.B superfamily.
Author: Originally, the bone inductive substances were
individually studied and names such as bone morphogenetic protein , osteogenin, and osteogenic protein-I
(OP-1) were used. While these names still exist, it has
now become evident that they are all members of a
larger group of peptides called the TGF-.B superfamily.
This family of peptides now includes several BMPs, all
of the TGF-,B's, as well as other substances such as
activins, inhibins, and the decapentaplegic gene expressed in Drosophila. Undoubtedly, as time goes on,
other peptides will be identified within this family and
the functions of each peptide will become more clear.
What is important to understand is that there is significant homology and overlap between the various substances identified and the potential clinical applications
of each of these substances may possibly be enhanced by
their combined use.

Discussion with Reviewers

J.M. Lane: The readers would benefit from a table of
the growth factors and their proposed function .
Author: I fully agree with you. However, a careful
and comprehensive review of the literature on growth
factors shows that no such table has ever been developed. The most probable reason to account for this is
the fact that the reported functions of these growth factors may be highly dependent on the conditions under
which they were investigated. The same growth factor
may have opposite effects in in vitro culture systems
when compared to an in vivo setting. Moreover, there
may be a dose dependency of growth factor function
such that at low concentrations it may have one set of
functions while at high concentrations it has another. In
several places in the text, I have attempted to indicate
how a specific factor may function based upon what has
been shown. However, it would be misleading to provide a table which would simplify the information on
this subject since the information unfortunately cannot be
simplified in this manner.

J.

Glowacki: With regard to prevention of non-unions
by treating fresh fractures with bone-promoting substances, what is the frequency of non-unions in various
bones and what are the predisposing features?
Author: The most accurate data on the frequency of
occurrence of musculoskeletal injures is documented by
a variety of subcommittees of the American Academy of
Orthopaedic Surgeons. Presently, it is estimated that
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